TGFB1 and cancer: Due to high immune and stromal cell infiltration in the stroma-rich subtype, TGF-β signaling inhibitors can prevent interactions among cancer cells and the TME avoids the progression of stromal-enriched CRC tumors with a poor prognosis (79).